Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T20:05:00.944Z.
Calculation as of: 2026-10-06T20:05:00.944Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4bd4e0dbd4a7a93fa478f826dfbb4c5faa0838165ed73afdd7809c26b653191f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
WORK Medical Technology Group Ltd. Class A
Market Cap
$3.63M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.67M
PS Ratio
N/A
TTM Avg
2863.91
3Y Avg
2004.87
5Y Avg
2004.87
Market Cap
$3.53M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.49M
PS Ratio
N/A
TTM Avg
141717.15
3Y Avg
141717.15
5Y Avg
141717.15
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| WORK Medical Technology Group Ltd. Class A (WOK) | $3.63M | N/A | N/A | N/A | N/A |
| Evogene Ltd. (EVGN)vs › | $3.65M | 2.79 | 2.12 | 1.98 | 176.94 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.67M | N/A | 2863.91 | 2004.87 | 2004.87 |
| Moolec Science S.A. (MLEC)vs › | $3.54M | N/A | 2.56 | 108.40 | 108.40 |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | N/A | N/A | N/A | N/A |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | 141717.15 | 141717.15 | 141717.15 |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | N/A | 1.94 | 5.55 | 4.76 |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | 15.20 | 54.87 | 78.32 | 59.55 |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.96M | 3.56 | 2.69 | 11.87 | 15.54 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
